These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34155478)

  • 21. TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis.
    Phan NH; Chun HJ; Oh JS; Kim SH; Choi BG
    Abdom Radiol (NY); 2024 Sep; ():. PubMed ID: 39320494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study.
    Huang Q; Lin K; Wang L; Zeng J; Liu H; Ding Z; Zeng Y; Liu J
    Cancer Manag Res; 2020; 12():9183-9195. PubMed ID: 33061610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
    Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
    Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
    Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
    JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis.
    Qiu Z; Shen L; Chen S; Qi H; Cao F; Xie L; Fan W
    Cancer Manag Res; 2019; 11():9321-9330. PubMed ID: 31802950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice.
    Li S; Mei J; Wang Q; Shi F; Liu H; Zhao M; Lu L; Ling Y; Guo Z; Guo Y; Chen X; Shi M; Lau WY; Wei W; Guo R
    Hepatobiliary Surg Nutr; 2021 Oct; 10(5):631-645. PubMed ID: 34760967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial Chemoembolization (TACE) Combined with Sorafenib
    Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
    J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis.
    Kim GH; Choi SL; Kim JH; Shim JH; Alali M; Kim N
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
    Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
    Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
    J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Yang ZW; He W; Zheng Y; Zou RH; Liu WW; Zhang YP; Wang CW; Wang YJ; Yuan YC; Li BK; Yuan YF
    J Cancer; 2018; 9(21):4000-4008. PubMed ID: 30410605
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis.
    Yang XG; Sun YY; Wang HQ; Li DS; Xu GH; Huang XQ
    Front Oncol; 2022; 12():914385. PubMed ID: 36176392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
    Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
    Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis.
    Cui R; Wang XH; Ma C; Liu T; Cheng ZG; Han ZY; Liu FY; Yu XL; Yu J; Liang P
    Cancer Manag Res; 2019; 11():10695-10704. PubMed ID: 31920380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study.
    Wang Y; Shen J; Feng S; Liang R; Lai J; Li D; Peng B; Wang Z; Huang C; Kuang M
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2220-2228. PubMed ID: 32246889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.
    Yao M; Cheng S; Zhai X; Zhao H; Hong J; Li X; Meng Y; Chen W
    Appl Bionics Biomech; 2022; 2022():9084852. PubMed ID: 36091626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.